CBMS extends funding for Cleveland BioLabs countermeasure

Cleveland BioLabs, Inc., a Buffalo, New York-based clinical stage biotechnology company, announced a $1.5 million funding award on Thursday from the U.S. Department of Defense as part of an existing development contract.

The DOD's Chemical Biological and Medical Systems Medical Information and Treatment Systems program awarded Cleveland BioLabs the contract in September 2010. The contract funded the company's development and stockpiling of its Entolimod drug, a countermeasure for radiation, Business First Buffalo reports.

The $14.8 million initially funded contract provided options for the purchase of $30 million worth of doses upon licensing from the Food and Drug Administration.

The $1.5 million in additional funding will support the company's studies on non-human primates.

Yakov Kogan, the CEO of Cleveland BioLabs, said the reallocation of funds shows that the government is confident the studies will help the development of Entolimod.

"The CBMS modification will assist us in performing at least one of the necessary pivotal animal studies," Kogan said, according to Business First Buffalo. "Our objective is to advance Entolimod to licensure under the FDA's animal rule as soon as possible, and position it for potential acquisition in the U.S. and globally."

Earlier this month, Cleveland BioLabs requested that the Biomedical Advanced Research and Development Authority provide the company with a $50 million funding boost to complete development steps for licensing Entolimod, Business First Buffalo reports.

Organizations in this Story

U.S. Department of Defense

Want to get notified whenever we write about U.S. Department of Defense ?
Next time we write about U.S. Department of Defense, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.